Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Testosterone Cypionate | Testosterone Enanthate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement therapy. | Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement. |
| Timing | Inject on a consistent schedule. Twice-weekly dosing (e.g., Monday/Thursday) reduces peak-trough fluctuations. Morning injection preferred for alignment with circadian testosterone rhythm. | Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate. |
| Cycle Duration | Ongoing for TRT. If discontinuing, taper and implement PCT protocol. Testicular function suppression occurs within 2-4 weeks of initiation. | Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation. |
| Evidence Level | strong_human | strong_human |
Testosterone cypionate is an esterified prodrug of testosterone that undergoes hydrolysis in vivo to release free testosterone. It binds the androgen receptor (AR), activating genomic pathways via AR nuclear translocation and transcription of anabolic genes including IGF-1, satellite cell proliferation, and nitrogen retention. Additionally, testosterone exerts non-genomic effects through membrane-associated AR signaling, modulating calcium influx and MAPK/ERK pathways. Aromatization to estradiol via CYP19A1 (aromatase) maintains bone density and lipid profiles.
Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement therapy.
Inject on a consistent schedule. Twice-weekly dosing (e.g., Monday/Thursday) reduces peak-trough fluctuations. Morning injection preferred for alignment with circadian testosterone rhythm.
Ongoing for TRT. If discontinuing, taper and implement PCT protocol. Testicular function suppression occurs within 2-4 weeks of initiation.
Testosterone enanthate is a long-acting esterified testosterone prodrug with a heptanoic acid ester at the 17-beta hydroxyl group, extending its half-life to approximately 4.5-5 days. Upon hydrolysis by tissue esterases, free testosterone activates nuclear androgen receptors, upregulating anabolic gene transcription including myostatin suppression and IGF-1 induction. It also modulates the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback on GnRH and LH secretion.
Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement.
Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate.
Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →